SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE Russian patent published in 2023 - IPC C07D231/18 C07D207/38 C07D213/74 C07D235/02 C07D241/24 C07D249/12 C07D261/18 C07D271/12 C07D277/36 C07D333/34 C07D307/64 C07D311/60 C07D401/06 C07D403/12 C07D405/12 C07D407/12 C07D413/12 C07D495/06 C07D498/04 A61K31/64 A61K31/18 A61K31/41 A61K31/4164 A61K31/4192 A61P1/00 A61P9/00 A61P11/00 A61P13/12 A61P15/00 A61P17/00 A61P25/00 A61P31/00 A61P35/00 A61P37/00 

FIELD: pharmaceutical chemistry.

SUBSTANCE: compound of formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, a method for treatment, a method for inhibiting the activity of a biological target, and the use of a compound of formula (I). In formula (1): W is selected from O, S and Se; J is selected from S and Se; R₁ is selected from the group consisting of 5-membered and 6-membered heterocyclyl, each of which contains 1 to 4 heteroatoms selected from N, O and S, and each of which may be optionally substituted, where any optional substituent is independently selected from the group consisting of C_1-10 alkyl; C_3-6 cycloalkyl; C_1-9 hydroxyalkyl; C_1-10 alkoxy; C_2-10 alkenyl; C_2-10 alkynyl; C₆-C₁₂ aryl; a heterocyclyl containing 5 to 8 ring atoms and of these atoms, 1 to 4 are heteroatoms selected from N, O and S; halo; hydroxyl; halogenated C_1-9 alkyl; amino; C_1-9 alkylamino; acyl; amido; CN; NO₂; N₃; CH₂OH; CONH₂; CONR₂R₂₅; CO₂R₂₄; CH₂OR₂₄; NHCOR₂₄; NHCO₂R₂₄; C_1-3 alkylthio; sulfonic acid; trityl; monomethoxytrityl; R₂₄SO; R₂₄SO₂; CF₃S; CF₃SO₂; and trialkylsilyl; where R₂₄ and R₂₅ are each independently selected from H or C_1-10 alkyl; R₂ is selected from 2,6-dialkylphenyl, 2,6-dialkyl-4-halophenyl, 2,6-dicycloalkylphenyl, 2,6-dicycloalkyl-4-halophenyl and , where each occurrence of Y is independently selected from C, N, S and O, which may be optionally substituted, where any optional substituent is independently selected from the group consisting of C_1-10 alkyl; C_3-6 cycloalkyl; C_1-9 hydroxyalkyl; C_1-10 alkoxy; C_2-10 alkenyl; C_2-10 alkynyl; C₆-C₁₂ aryl; a heterocyclyl containing 5 to 8 ring atoms and of these atoms, 1 to 4 are heteroatoms selected from N, O and S; halo; hydroxyl; halogenated C_1-9 alkyl; amino; C_1-9 alkylamino; acyl; amido; CN; NO₂; N₃; CH₂OH; CONH₂; CONR₂₄R₂₅; CO₂R₂₄; CH₂OR₂₄; NHCOR₂₄; NHCO₂R₂₄; C_1-3 alkylthio; sulfonic acid; trityl; monomethoxytrityl; R₂₄SO; R₂₄SO₂; CF₃S; CF₃SO₂; and trialkylsilyl; where R₂₄ and R₂₅ are each independently selected from H or C_1-10 alkyl; R₅ is selected from the group consisting of hydrogen, halo, cyano, amide, sulfonamide, acyl, hydroxyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₅ cycloalkyl and C₁-C₆ alkoxy, all of which may be optionally substituted with halo, cyano or C₁-C₆ alkoxy; and as R₁ is directly bonded to J, so is R₂ directly bonded to the adjoining nitrogen atom via a carbon atom; provided that when W is O, J is S, and R₁ is a 5-membered heterocyclyl, then this 5-membered heterocyclyl does not contain any ring nitrogen atoms.

EFFECT: compound of formula (I) having the properties of an inhibitor of NLRP3 inflammasome activation, used for the treatment of diseases that respond to inhibition of NLRP3 inflammasome activation.

29 cl, 6 dwg, 10 tbl